Apex Biotechnology Valuation
| 1733 Stock | TWD 34.00 0.15 0.44% |
At this time, the firm appears to be undervalued. Apex Biotechnology Corp shows a prevailing Real Value of NT$38.45 per share. The current price of the firm is NT$34.0. Our model approximates the value of Apex Biotechnology Corp from analyzing the firm fundamentals such as return on equity of 0.13, and Profit Margin of 0.1 % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Apex Biotechnology's price fluctuation is very steady at this time. Calculation of the real value of Apex Biotechnology Corp is based on 3 months time horizon. Increasing Apex Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Apex stock is determined by what a typical buyer is willing to pay for full or partial control of Apex Biotechnology Corp. Since Apex Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Apex Stock. However, Apex Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 34.0 | Real 38.45 | Hype 34.0 |
The intrinsic value of Apex Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Apex Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Apex Biotechnology Corp helps investors to forecast how Apex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Apex Biotechnology more accurately as focusing exclusively on Apex Biotechnology's fundamentals will not take into account other important factors: Apex Biotechnology Total Value Analysis
Apex Biotechnology Corp is presently anticipated to have takeover price of 2.45 B with market capitalization of 2.57 B, debt of 526.89 M, and cash on hands of 523.23 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Apex Biotechnology fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.45 B | 2.57 B | 526.89 M | 523.23 M |
Apex Biotechnology Investor Information
About 16.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.46. In the past many companies with similar price-to-book ratios have beat the market. Apex Biotechnology Corp last dividend was issued on the 16th of June 2022. The entity had 1:1 split on the 1st of July 2009. Based on the key measurements obtained from Apex Biotechnology's financial statements, Apex Biotechnology Corp is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Apex Biotechnology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Apex Biotechnology has an asset utilization ratio of 79.82 percent. This indicates that the Company is making NT$0.8 for each dollar of assets. An increasing asset utilization means that Apex Biotechnology Corp is more efficient with each dollar of assets it utilizes for everyday operations.Apex Biotechnology Ownership Allocation
Apex Biotechnology holds a total of 99.95 Million outstanding shares. Apex Biotechnology Corp shows 15.5 percent of its outstanding shares held by insiders and 2.52 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Apex Biotechnology Profitability Analysis
The company reported the revenue of 2.13 B. Net Income was 202.22 M with profit before overhead, payroll, taxes, and interest of 571.51 M.About Apex Biotechnology Valuation
Our relative valuation model uses a comparative analysis of Apex Biotechnology. We calculate exposure to Apex Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Apex Biotechnology's related companies.Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of medical devices by using biosensor technology worldwide. Apex Biotechnology Corp. was founded in 1997 and is headquartered in Hsinchu, Taiwan. APEX BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.
8 Steps to conduct Apex Biotechnology's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Apex Biotechnology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Apex Biotechnology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Apex Biotechnology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Apex Biotechnology's revenue streams: Identify Apex Biotechnology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Apex Biotechnology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Apex Biotechnology's growth potential: Evaluate Apex Biotechnology's management, business model, and growth potential.
- Determine Apex Biotechnology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Apex Biotechnology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Apex Stock Analysis
When running Apex Biotechnology's price analysis, check to measure Apex Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apex Biotechnology is operating at the current time. Most of Apex Biotechnology's value examination focuses on studying past and present price action to predict the probability of Apex Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apex Biotechnology's price. Additionally, you may evaluate how the addition of Apex Biotechnology to your portfolios can decrease your overall portfolio volatility.